Core 3: Pathology & Biospecimens Core

总结/摘要 获取相关生物标本对于少数群体转化研究至关重要。缺乏 来自美国种族和少数民族的研究标本仍然是理解的障碍 癌症发展、进展和结局的种族/民族差异。特别是，缺乏临床 来自未充分研究的人群的生物标本，包括夏威夷原住民，其他太平洋岛民和亚洲人。 美国人解决影响这些美国人的癌症风险和结果的关键差异的能力有限。 社区.夏威夷是美国种族最多样化的州， 常见的癌症--包括肝癌、乳腺癌、肺癌、结肠直肠癌、子宫内膜癌和胃癌，与美国相比， 总的来说。此外，在夏威夷独特的多民族多元社会中， 包括夏威夷原住民在内的人口中，乳腺癌、肝、肺和其他常见疾病的死亡率最高。 恶性肿瘤在夏威夷大学癌症中心（UHCC）收集的生物标本的价值是 这在其翻译研究的广度和范围上显而易见。尽管取得了这一进展， 迄今为止，UHCC已被破碎，并限于某些类型的标本，特别是新鲜冷冻肿瘤 组织.目前的UHCC生物标本资源包括全州范围内的临床注释，去识别的 存档福尔马林固定石蜡包埋（FFPE）肿瘤组织，并前瞻性和回顾性收集 血液、尿液、口腔冲洗液和粪便。相比之下，收集新鲜冷冻组织 在很大程度上限于小规模收集不同的制药商发起的研究。有一个至关重要的 UHCC需要标准化和集中收集癌症患者的新鲜冷冻肿瘤和血液 在我们参与的社区医院，并将这些收集与现有资源相结合， 优化它们在癌症研究中的效用。我们建议开发病理学和生物标本核心， 整合和增加现有的和新的生物标本资源， 处理、跟踪、储存和分发，并将支持项目1（NASH/肝癌）、项目2（肺癌）、项目3（非酒精性脂肪性肝炎）和项目4（肺癌）。 癌症），项目3（乳腺癌），职业提升计划（CEP）和发展研究计划 (DRP)项目，以及其他UHCC调查，目标是开发一个强大的基础设施， 解决亚裔美国人、夏威夷原住民和太平洋岛民的癌症风险和结局差异 （AANHPI）少数民族人口。目标1将集中于发展一个成对的新鲜冷冻 肿瘤组织和血液样本来自夏威夷州诊断为癌症的多种族癌症病例 肺、肝、乳腺、结肠直肠、子宫内膜、胰腺和胃。将通过以下方式确定潜在病例： 通过NCI SEER夏威夷肿瘤登记处从全州医疗机构快速报告。对于目标2， 将从新的和现有的资源中提供生物标本，以支持项目1、2和3、CEP和DRP 未来的癌症研究项目。

SUMMARY /ABSTRACT Access to relevant biospecimens is critical to translational research on minority populations. The lack of research specimens from racial and ethnic minority populations in the U.S. remains a barrier to understanding racial/ethnic differences in cancer development, progression, and outcomes. In particular, the paucity of clinical biospecimens from understudied populations, including Native Hawaiians, other Pacific Islanders, and Asian Americans has limited the ability to address critical disparities in cancer risk and outcomes affecting these U.S. communities. Hawaiʻi, the most ethnically diverse state in the nation, has experienced a higher burden of common cancers-- including liver, breast, lung, colorectum, endometrium, and stomach, compared to the U.S overall. Moreover, wide racial and ethnic disparities are observed within Hawaiʻi's uniquely diverse multiethnic population including Native Hawaiians who have the highest mortality for breast, liver, lung, and other common malignancies. The value of the biospecimens collected at the University of Hawaiʻi Cancer Center (UHCC) is evident in the breadth and scope of its translational research. Despite this progress, biorepository efforts at the UHCC to date have been fragmented and limited for certain types of specimens, especially fresh frozen tumor tissue. Current UHCC biospecimen resources include a statewide repository of clinically-annotated, de-identified archival formalin-fixed paraffin-embedded (FFPE) tumor tissue and prospectively and retrospectively collected blood, urine, oral rinses, and stool from consented individuals. In contrast, the collection of fresh frozen tissue has been largely limited to small scale collections for disparate investigator-initiated studies. There is a crucial need at UHCC to standardize and centralize the collection of fresh frozen tumor and blood from cancer patients in our participating community hospitals and to integrate these collections with existing resources in order to optimize their utility for cancer research. We propose to develop a Pathology and Biospecimen Core that will integrate and augment existing and new biospecimen resources with respect to their acquisition, processing, tracking, storage, and distribution and will support Project 1 (NASH/liver cancer), Project 2 (lung cancer), Project 3 (breast cancer), Career Enhancement Program (CEP) and Developmental Research Program (DRP) projects, as well as other UHCC investigations with the goal of developing a robust infrastructure to address differences in cancer risk and outcomes in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) ethnic minority populations. Aim 1 will focus on the development of a repository of paired fresh frozen tumor tissue and blood specimens from multiethnic cancer cases diagnosed in the state of Hawaiʻi with cancers of the lung, liver, breast, colorectum, endometrium, pancreas, and stomach. Potential cases will be identified via rapid reporting from medical facilities statewide through the NCI SEER Hawaiʻi Tumor Registry. For Aim 2, we will provide biospecimens from new and existing resources in support of Projects 1, 2, and 3, CEP and DRP projects, and future cancer research projects.